Cost-Effectiveness of 18FDG-PET/CT Compared to CT Followed by 18FDG-PET/CT as a Confirmatory Test for a Positive Case in the Evaluation at the End of Treatment in Patients with Hodgkin Lymphoma

2012 ◽  
Author(s):  
Mario García Molina ◽  
Liliana Chicaíza ◽  
Alexander Moreno Calderón ◽  
Víctor Prieto Martínez ◽  
Adriana Linares Ballesteros ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hodgkin Lymphoma ◽  
Positive Case ◽  
Confirmatory Test ◽  
18Fdg Pet ◽  
End Of Treatment ◽  
Pet Ct

Prognostic role of interim 18FDG-PET in Hodgkin lymphoma: A single-center experience

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19520-e19520 ◽  
Author(s):  
E. Cocorocchio ◽  
A. Vanazzi ◽  
E. Botteri ◽  
A. Alietti ◽  
M. Negri ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Randomized Clinical Trials ◽  
Fisher Exact Test ◽  
Prognostic Role ◽  
Bulky Disease ◽  
18Fdg Pet ◽  
End Of Treatment

e19520 Background: The role of FDG-PET for staging and response assessment in Hodgkin lymphoma (HL) is still evolving. We report our experience with the intent of evaluate prognostic role of 18FDG-PET in terms of long term complete remission (CR). Methods: We retrospectively analysed 65 consecutive pts affected by newly diagnosed HL. Median age was 36 yrs. Histology included 50 classical and 10 lymphocyte predominance HL. According to Hasenclever index, 58 out of 65 pts were considered at low risk, 5 at intermediate and 2 at high risk. 30/65 pts showed good prognosis (defined as IA-IIA, < 3 nodal sites, ERS < 50) and received 4 cycles of VBM followed by involved field (IF) radiotherapy (RT); the remaining 35 pts received hybrid ChlVPP/ABVVP for 6 cycles followed by IF RT in case of bulky disease. All patients underwent 18FDG-PET scans at diagnosis, after the fourth cycle in the VBM group, after the third cycle in the ChlVPP/ABVVP (interim 18FDG-PET), at the end of treatment in all patients. Fisher exact test was used to compare percentages between groups. Results: CR was recorded in 60 (92%) pts. Interim 18FDG-PET was negative in 52 out of 65 pts (80%), all in CR at the end of treatment. Eight out of 13 pts with positive interim 18FDG-PET obtained a CR at the end of treatment (100% versus 62%, Fisher exact text p<0.01). Six out of 65 pts relapsed: interim 18FDG-PET was negative in 5 of them, positive in 1 case. Two deaths occurred, one among pts with negative and one with positive interim 18FDG-PET. After a median follow-up of 30 months, 3-year freedom from treatment failure was 83% and 62% in pts with negative and positive interim 18FDG-PET, respectively (Log-rank test p<0.01, Hazard Ratio 4.9 (95%CI 1.4–16.1)). Conclusions: In our experience interim 18FDG-PET demonstrate a predictive role regarding the achievement of CR and treatment failure, at least as relevant as Hasenclever index, but failed to predict clinical result in 12 (18%) pts. Its role in defining the best therapeutical approach in HL pts must be further investigated in randomized clinical trials. No significant financial relationships to disclose.

scholarly journals Cost-Effectiveness of The Use of 18fdg-Pet/Ct In The Detection of Recurrent Differentiated Thyroid Cancer

2015 ◽  
Vol 18 (7) ◽  
pp. A859
Author(s):  
AN Biz ◽  
LF Schluckebier ◽  
CR Bastos ◽  
RM Silva ◽  
JU Braga ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cost Effectiveness ◽  
Differentiated Thyroid Cancer ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals Prognostic value of interim and end of treatment PET-CT scan results in pediatric Hodgkin lymphoma

2020 ◽  
Vol 5 (4) ◽  
pp. S23
Author(s):  
Mohyeldin Saber Abdelhalim ◽  
Omar Shebl ◽  
Nadia Eldeeb ◽  
Shady Fadel
Keyword(s):  
Ct Scan ◽  
Hodgkin Lymphoma ◽  
Prognostic Value ◽  
Pediatric Hodgkin Lymphoma ◽  
End Of Treatment ◽  
Pet Ct ◽  
Pet Ct Scan

scholarly journals THE ROLE OF END OF TREATMENT PET CT EVALUATED BY DEAUVILLE FIVE‐POINT SCALE AS PROGNOSTIC ROLE IN HODGKIN LYMPHOMA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
G. M. Assanto ◽  
R. Agrippino ◽  
G. Lapietra ◽  
M. L. De Luca ◽  
A. Chiaravalloti ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Point Scale ◽  
Prognostic Role ◽  
End Of Treatment ◽  
Pet Ct

scholarly journals Improvements in Clinical Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the United States from 2000-2014: Analysis of Surveillance Epidemiology and End Results Database

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2939-2939
Author(s):  
Guru Subramanian Guru Murthy ◽  
Aniko Szabo ◽  
Mehdi Hamadani ◽  
Timothy S. Fenske ◽  
Nirav N Shah
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Clinical Outcomes ◽  
Research Funding ◽  
Advanced Stage ◽  
End Of Treatment ◽  
Pet Ct ◽  
Equity Ownership ◽  
Time Periods ◽  
Over Time

Abstract Background: Advanced Stage Hodgkin lymphoma (HL) is a curable malignancy with combination chemotherapy. While most patients are cured with frontline therapy, for those with refractory disease or early progression, historically, the outcomes have been poor. Novel therapies, PET/CT adapted treatment approaches, and improvement in transplantation have changed the management of both frontline and relapsed HL. However, it remains unknown if these developments have improved the clinical outcomes at population level over time. Methods: Using Surveillance Epidemiology and End Results database, we identified patients aged ≥ 18 years with advanced stage (Stage III or IV) pathologically confirmed classical HL as the first primary malignancy,diagnosed between the years 2000-2014, treated with chemotherapy and actively followed. Patients were stratified by date of diagnosis into 3 groups - 2000-2004, 2005-2009, 2010-2014 to assess the trends in overall survival (OS) over time. Race/ethnicity was stratified into non-hispanic whites and minorities (Non-hispanic blacks, Hispanics, other non-hispanic races). Kaplan-Meier method and log rank test were used to analyze the OS among subgroups. Cox proportional hazard regression method was used to determine the influence of period and demographic factors on OS.Cumulative incidence of death from cardiac cause was estimated using the Nelson-Aalen estimates. Statistical analyses were carried out with significant two sided p< 0.05. Results: A total of 9042 patients with a median age of 41 years were included. There were more males (60.1%) and non-Hispanic whites (64.2%) and most patients had nodal disease (98%) (Table 1).The use of frontline radiation therapy decreased in each 5-year time period (21.3% 2000-2004 vs 15.5% 2005-2009 vs 10.7% 2010-2014, p<0.001). In terms of survival, when stratified by the period of diagnosis, the 3-year OS was significantly higher for patients diagnosed between the year 2010-2014 (81.8%) and 2005-2009 (80.6%) than those diagnosed from 2000-2004 (78.5%, p=0.0008 and 0.02 respectively) (Figure 1). Additionally, age was a significant predictor for OS with a decreasing 3-year OS with increasing age (age < 40 - 91.1%, age 41-60 -81.5%, age >60 -54%, p< 0.001, Figure 2).While outcomes were poorest in the age>60 cohort, similar improvements were seen in OS over the three time periods among this patient population (48.6%- 2000-2004 vs 54.3% 2005-2009 vs 56.8% 2010-2014, p=0.005). On multivariate analysis, diagnosis in the earlier period was associated with higher mortality (2000-2004-HR 1.36, 95% CI 1.21-1.53, p< 0.001; 2005-2009 -HR 1.14, 95% CI 1.01-1.28, p=0.02, both compared to reference group 2010-2014). Similarly, minority races (HR 1.36, 95%CI 1.23-1.49, p<0.001) had a higher mortality risk as compared to non-Hispanic whites. Females (HR 0.82, 95%CI 0.75-0.90 p<0.001) and married status (HR 0.80, 95%CI 0.72-0.87, p< 0.001) were associated with significantly lower mortality. While radiation use decreased over time, the cumulative incidence of cardiac related cause of death did not vary significantly among the three-time periods (1.2% vs 1.1% vs 1.1% respectively at 48 months, p=0.85). Conclusions: Survival of patients with advanced stage HL has continued to improve over time suggesting the clinical impact of evolving treatment approaches. Interestingly this improvement has occurred despite the decreasing utilization of radiation therapy over time. This is suggestive of better end of treatment assessment with PET/CT eliminating the need for end of treatment radiation, improved second line therapies that extend survival, or potentially reduction in treatment related toxicities.Despite these encouraging results, the 3-year OS in the contemporary period remains inadequate at 81.8%. Furthermore, significant differences in survival continue to exist among non-modifiable factors such as gender, age, race, and marital status, highlighting the need for continued research to address these discrepancies. Results of this study provide a new baseline to test novel frontline combination regimens. Disclosures Hamadani: Takeda: Research Funding; Celgene Corporation: Consultancy; Cellerant: Consultancy; Ostuka: Research Funding; Janssen: Consultancy; MedImmune: Consultancy, Research Funding; Merck: Research Funding; ADC Therapeutics: Research Funding; Sanofi Genzyme: Research Funding, Speakers Bureau. Shah:Miltenyi: Other: Travel funding, Research Funding; Exelexis: Equity Ownership; Oncosec: Equity Ownership; Geron: Equity Ownership; Juno Pharmaceuticals: Honoraria; Lentigen Technology: Research Funding.

Whole body diffusion-weighted MRI to predict treatment outcome after one cycle of immunochemotherapy in aggressive non-Hodgkin lymphoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 7534-7534
Author(s):  
Katja De Paepe ◽  
Frederik De Keyzer ◽  
Oliver Bechter ◽  
Ciska-Anne Van Keerberghen ◽  
Olivier Gheysens ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Treatment Outcome ◽  
Hodgkin Lymphoma ◽  
Hazard Ratio ◽  
Whole Body ◽  
Interim Pet ◽  
Non Hodgkin Lymphoma ◽  
Diffusion Weighted ◽  
End Of Treatment ◽  
Pet Ct

7534 Background: Treatment adaptation based on early identification of non-Hodgkin lymphoma (NHL) patients not responding to therapy might improve survival. The role of interim fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) after 2-4 cycles of immunochemotherapy (ICT) herein is experimental as it renders false positive results, due to a rituximab-induced inflammatory response. Whole body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) was evaluated as a radiation-free imaging technique to predict treatment outcome in NHL after one cycle ICT (2-3 weeks). Methods: 47 patients with aggressive NHL (35 DLBCL,2 primary mediastinal BCL,3 unclassifiable BCL, 2 Burkitt,2 MCL, 2 peripheral TCL and 1 extranodal NK-TCL) were enrolled. All had baseline and interim WB-DWI/MRI, and end-of-treatment PET/CT; 39/47 had interim PET/CT. International prognostic index (IPI), immunohistochemical (IHC) markers Ki-67, Bcl-6 and Bcl-2 were evaluated for their predictive value. WB-DWI/MRI was assessed quantitatively with histogram analysis (high b-value signal intensity (SI) and apparent diffusion coefficient (ADC)). Patients were categorized as non-responder when lesions had decreased ADC or insufficient SI decrease between scans. Kaplan-Meier survival analysis was performed with log rank, Cox hazard ratio calculation and multivariate analysis. Outcome measure was disease-free-survival (DFS). Results: Median follow-up time was 43 months (4-70 months). 33 patients had complete remission (CR), 5 progression and 9 recurrent disease. WB-DWI/MRI predicted DFS correctly in 45/47 (96%) [log rank p<0.001; hazard ratio (HR) 52, (CI 95% 6-401)]; end-of-treatment PET/CT was correct in 37/47 (79%) [p=0.003;HR 4.3, (1.5-12.4)], and interim PET/CT in 28/39 (72%) [p=0.016;HR 3.9, (1.2-12.5)]. IPI score and IHC parameters were not significantly predictive. Multivariate analysis showed WB-DWI/MRI as the only independent prognostic factor (p<0.001). Conclusions: WB-DWI/MRI can accurately predict treatment outcome in aggressive NHL after only one cycle of immunochemotherapy without the burden of radiation exposure. Clinical trial information: NCT01231269.

Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mónica G. Rodríguez Taroco ◽  
Enrique G. Cuña ◽  
Carolina Pages ◽  
Magdalena Schelotto ◽  
Gabriel A. González-Sprinberg ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Prognostic Value ◽  
Paediatric Patients ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Imaging Markers

Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria

2017 ◽  
Vol 31 (9) ◽  
pp. 660-668 ◽  
Author(s):  
Emine Göknur Isik ◽  
Serkan Kuyumcu ◽  
Rejin Kebudi ◽  
Yasemin Sanli ◽  
Zeynep Karakas ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Point Scale ◽  
Prediction Of Outcome ◽  
Pediatric Hodgkin Lymphoma ◽  
18Fdg Pet ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document